Cobanoglu Ufuk, Sayir Fuat, Bilici Salim, Melek Mehmet
Abidin Şehitoğlu, Van State Hospital Department of Thoracic Surgery, Van, Turkey.
Pediatr Rep. 2011 Sep 30;3(4):e29. doi: 10.4081/pr.2011.e29. Epub 2011 Nov 28.
Today, in spite of the developments in imaging methods and antibiotherapy, childhood pleural empyema is a prominent cause of morbidity and mortality. In recent years, it has been shown that there has been an increase in the frequency of pleural empyema in children, and antibiotic resistance in microorganisms causing pleural empyema has made treatment difficult. Despite the many studies investigating thoracoscopic debridement and fibrinolytic treatment separately in the management of this disease, there is are not enough studies comparing these two treatments. The aim of this study was to prospectively compare the efficacy of two different treatment methods in stage II and III empyema cases and to present a perspective for treatment options.WE EXCLUDED FROM THE STUDY CASES WITH: i) thoracoscopic intervention and fibrinolytic agent were contraindicated; ii) immunosuppression or additional infection focus; iii) concomitant diseases, those with bronchopleural fistula diagnosed radiologically, and Stage I cases. This gave a total of 54 cases: 23 (42.6%) in stage II, and 31 (57.4%) cases in stage III. These patients were randomized into two groups of 27 cases each for debridement or fibrinolytic agent application by video-assisted thoracoscopic decortication (VATS). The continuity of symptoms after the operation, duration of thoracic tube in situ, and the length of hospital stay in the VATS group were of significantly shorter duration than in the streptokinase applications (P=0.0001). In 19 of 27 cases (70.37%) in which fibrinolytic treatment was applied and in 21 cases of 27 (77.77%) in which VATS was applied, the lung was fully expanded and the procedure was considered successful. There was no significant difference with respect to success rates between the two groups (P=0.533). The complication rate in our cases was 12.96% and no mortality was observed. Similar success rates in thoracoscopic drainage and enzymatic debridement, and the low cost of enzymatic drainage both served to highlight intrapleural streptokinase treatment as a reliable method in reducing the need for surgery in complicated empyema.
如今,尽管成像方法和抗微生物疗法有所发展,但儿童胸膜腔积脓仍是发病和死亡的一个重要原因。近年来,已表明儿童胸膜腔积脓的发生率有所增加,且引起胸膜腔积脓的微生物的抗生素耐药性使治疗变得困难。尽管有许多研究分别调查了胸腔镜清创术和纤维蛋白溶解治疗在该疾病管理中的应用,但比较这两种治疗方法的研究还不够。本研究的目的是前瞻性地比较两种不同治疗方法在Ⅱ期和Ⅲ期积脓病例中的疗效,并为治疗选择提供一个视角。我们将以下病例排除在研究之外:i)胸腔镜干预和纤维蛋白溶解剂禁忌;ii)免疫抑制或额外感染源;iii)合并疾病、经放射学诊断有支气管胸膜瘘的病例以及Ⅰ期病例。这共有54例:Ⅱ期23例(42.6%),Ⅲ期31例(57.4%)。这些患者被随机分为两组,每组27例,分别通过电视辅助胸腔镜剥脱术(VATS)进行清创或应用纤维蛋白溶解剂。VATS组术后症状持续时间、胸腔引流管留置时间和住院时间均明显短于链激酶应用组(P = 0.0001)。在应用纤维蛋白溶解治疗的27例中的19例(70.37%)以及应用VATS的27例中的21例(77.77%)中,肺完全复张,手术被认为成功。两组之间的成功率无显著差异(P = 0.533)。我们病例的并发症发生率为12.96%,未观察到死亡病例。胸腔镜引流和酶促清创的成功率相似,且酶促引流成本低,这两者都凸显了胸膜腔内链激酶治疗作为一种可靠方法,可减少复杂积脓手术需求。